Importance of pharmacokinetics in the management of hemophilia

Pediatric Blood and Cancer

Volumn 60, Issue SUPPL.1, 2013, Pages

  Barnes, Chris ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Hemophilia; Pharmacokinetics; Prophylaxis

Indexed keywords

ANTIBIOTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR CONCENTRATE; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

AREA UNDER THE CURVE; BODY WEIGHT; COMPARATIVE STUDY; DEVELOPED COUNTRY; DISEASE SEVERITY; DOSE CALCULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MONITORING; GOLD STANDARD; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MEAN RESIDENCE TIME; MONITORING; PRIORITY JOURNAL; REVIEW; WEIGHT;

CHILD; CHILD, PRESCHOOL; FACTOR IX; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMANS;

EID: 84869222261     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24339     Document Type: Review

References (22)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-544.
2. Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
3. Berntorp E, Astermark J, Bjorkman S, et al. Consensus perspectives on prophylactic therapy for haemophilia: Summary statement. Haemophilia 2003; 9: 1-4.
4. Lofqvist T, Nilsson IM, Berntorp E, et al. Haemophilia prophylaxis in young patients-A long-term follow-up. J Intern Med 1997; 241: 395-400.
5. van den Berg HM, Fischer K, Mauser-Bunschoten EP, et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-565.
6. Feldman BM, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: Interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-1236.
7. Yaffe S, Aranda J. Neonatal and pediatric pharmacology: Therapeutic principles in practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
8. Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: Clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-832.
9. Noe DA. A mathematical model of coagulation factor VIII kinetics. Haemostasis 1996; 26: 289-303.
10. Vlot AJ, Koppelman SJ, Meijers JC, et al. Kinetics of factor VIII-von Willebrand factor association. Blood 1996; 87: 1809-1816.
11. Fijnvandraat K, Peters M, ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995; 91: 474-476.
12. Bjorkman S, Blanchette VS, Fischer K, et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: The influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010; 8: 730-736.
13. Bjorkman S, Folkesson A, Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: A population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eu J Clin Pharmacol 2009; 65: 989-998.
14. Collins PW, Bjorkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: Influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269-275.
15. Thompson AR. Factor IX concentrates for clinical use. SeminThromb Haemost 1993; 19: 25-36.
16. Bjorkman S, Carlsson M, Berntorp E. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eu J Clin Pharmacol 1994; 46: 325-332.
17. Lee M, Morfini M, Schulman S, et al. Scientific and Standardisation Committee communication. The design and analysis of pharmacokinetic studies of coagulation factors. ISTH Website. 2001 [21 March 2001].
18. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992; 22: 447-467.
19. Tod MM, Padoin C, Petitjean O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: Simple or complex pharmacokinetic methods? Clin Pharmacokinet 2001; 40: 803-814.
20. Ting LS, Villeneuve E, Ensom MH. Beyond cyclosporine: A systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit 2006; 28: 419-430.
21. Bjorkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 2010; 16: 597-605.
22. Carlsson M, Berntorp E, Bjorkman S, et al. Improved cost effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997; 3: 96-101.